Pfizer has the mission to fund programs that provide public benefit, advance medical care, and can improve patient outcomes. Their researchers preform 25,000 clinical tests everyday for pharmaceutical development and innovations.
Pfizer is a partner with the BaseLaunch startup accelerator. The BaseLaunch program receives applications in the fields of therapeutics, diagnostics, digital healthcare, healthcare services, therapeutic platforms, and medical technology.
Insilico Medicine and Pfizer entered into a research collaboration agreement. The agreement allows Pfizer to utilize Insilico Medicine's machine learning technology and Pandomics Discovery Platform to research potential therapeutic targets for a variety of diseases.
AMRA Medical and Pfizer's partnership works to investigate body fat distribution and muscle composition in a range of diseases using the UK Biobank registry. The partnership involves the body composition analysis of 100,000 individuals.
Pfizer's partnership with CytoReason gives them access to CytoReason's machine learning platform for drug discovery and development.
XtalPi Inc. and Pfizer's research collaboration focuses on developing a hybrid physics-and artificial intelligence-powered software platform for accurate molecular modeling of small molecules. The platform is intended to advance both companies capabilities in drug design and solid-form selection.
Pfizer and Distributed Bio entered an agreement to license Distributed Bio's SuperHuman Platform to Pfizer. The SuperHuman 2.0 antibody discovery platform will allow Pfizer to utilize the antibody library for screening activities against Pfizer-selected targets.
Domain Therapeutics and Pfizer entered into a collaboration agreement to asses Domain Therapeutics's bioSensAll platform. The bioSensAll platform defines signaling signatures for each wild-type and mutant receptors. Pfizer aims to use the platform to assess the impact of mutations on different signaling pathways engaged by g protein-coupled receptors.
Pfizer announced that they have identified certain antiviral compounds that are under development which could be effective in treating the novel coronavirus SARS-CoV-2 responsible for COVID-19. They may enter a partnership with a third party company to screen and identify potential compounds by the end of March, 2020 in order to begin testing in April, 2020.
Pfizer is partnered with BioNTech for co-development and distribution of an mRNA vaccine against SARS-CoV-2 called BNT162.
Pfizer and Adage bump up Amplyx's series C to top $90 million.
Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets.
Pfizer announces an additional half billion dollar investment for the construction of its gene therapy manufacturing facility in Sanford, North Carolina.
Pfizer acquires Array BioPharma for $11.4 billion.
Pfizer Inc. acquires option to buy Vivet Therapeutics for equivalent of $635.8 million.
CytoReason signs collaboration agreement with Pfizer Inc. to utilize CytoReason's machine learning model of the immune system for drug discovery.
Pfizer's subsidiary, Pfizer Ventures, participated in System1's Series A financing.
System1 stated they will use the funding to drive its drug discovery programs for autism, epilepsy, and schizophrenia. Their system uses robot automation for the development of organoids and uses data analysis systems to analyze the resulting data streams.
XtalPi Inc. announces research collaboration with Pfizer Inc. to develop artificial intelligence-powered molecular modeling technology for drug discovery.
Pfizer supports the Centre for Process Innovation (CPI) and their technology for process manufacturing and nano-formulated medicines.
A molecular diagnostics company developing novel blood-based early detection and disease monitoring tests based on analyzing circulating cell-free messenger RNA (cf-mRNA) in blood samples to monitor organ function.
Trillium Therapeutics is a biotechnology company developing cancer immunotherapies.
Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs.
SpringWorks Therapeutics is a Stamford, Connecticut-based company founded in 2017 by Lara S. Sullivan.
FoRx Therapeutics is a Basel-based biotechnology company developing a drug discovery platform for cancer drugs.
Arrakis Therapeutics is a Waltham, Massachusetts-based company.
Imara is a Cambridge, Massachusetts-based company.
Strata is a Lake Forest, California-based company founded in 1995.
Aquinnah Pharmaceuticals is a Cambridge, Massachusetts-based company.
Abdalrahman Mekky, CMA
Abraham Svinkelstin, PMP, MS, MS, CSSGB
Alec Robert Gilarde
Alexander H. Buell
Breaking the Rules of Biology to Beat Rare Genetic Disease | Pfizer
Our Science: Pharmaceutical Development | Pfizer | Pfizer
Pfizer | Crunchbase
Pfizer's Core Values of Social Responsibility and Philanthropy | Pfizer
What to Know About Coronavirus -- COVID-19 Explained | Pfizer
Documentaries, videos and podcasts
New York, New York, United States
Medical, healthcare, biotechnology, and pharmaceutical products and services
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.
- CoronavirusCDC Coronavirus: Coronaviruses are common throughout the world. They can infect people and animals. Five different coronaviruses can infect people and make them sick. They usually cause mild to moderate upper-respiratory illness.
- HealthcareDiagnosis, treatment and prevention of disease, illness, and injury